Trial Profile
SARC029: A Phase 2 Study of Trametinib in Combination With Pazopanib in Patients With Advanced GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2017
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Trametinib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- 08 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as supporting company withdrew interest
- 28 Mar 2016 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020 as reported by ClinicalTrials.gov.
- 28 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.